Vertex Pays Below-Market Multiple for Crinetics, Signaling Confidence in Upside

Vertex's $8.8 billion enterprise value for Crinetics translates to 1.76x peak sales—below the typical 2–4x range for rare-disease M&A. That discount suggests Vertex sees material upside beyond the $5 billion peak sales estimate for Crinetics' endocrinology assets, particularly Palsonify, a drug for acromegaly. The valuation rewards execution risk but reflects discipline: Vertex isn't overpaying for late-stage rare-disease assets in a competitive M&A environment.